Abbas N - Search Results

1

Advantage of lutetium-177 versus radioiodine immunoconjugate in targeted radionuclide therapy of b-cell tumors.

Repetto-Llamazares A, Abbas N, Bruland ØS, Dahle J, Larsen RH. Repetto-Llamazares A, et al. Among authors: abbas n. Anticancer Res. 2014 Jul;34(7):3263-9. Anticancer Res. 2014. PMID: 24982330

2

Targeted alpha therapy with 227Th-trastuzumab of intraperitoneal ovarian cancer in nude mice.

Heyerdahl H, Abbas N, Sponheim K, Mollatt C, Bruland Ø, Dahle J. Heyerdahl H, et al. Among authors: abbas n. Curr Radiopharm. 2013 Jun 6;6(2):106-16. doi: 10.2174/18744710113069990018. Curr Radiopharm. 2013. PMID: 23551111

3

Evaluation of CD146 as Target for Radioimmunotherapy against Osteosarcoma.

Westrøm S, Bønsdorff TB, Abbas N, Bruland ØS, Jonasdottir TJ, Mælandsmo GM, Larsen RH. Westrøm S, et al. Among authors: abbas n. PLoS One. 2016 Oct 24;11(10):e0165382. doi: 10.1371/journal.pone.0165382. eCollection 2016. PLoS One. 2016. PMID: 27776176 Free PMC article.

4

Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates.

Dahle J, Abbas N, Bruland ØS, Larsen RH. Dahle J, et al. Among authors: abbas n. Curr Radiopharm. 2011 Oct;4(4):321-8. doi: 10.2174/1874471011104040321. Curr Radiopharm. 2011. PMID: 22202154 Review.

5

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab.

Abbas N, Heyerdahl H, Bruland OS, Borrebæk J, Nesland J, Dahle J. Abbas N, et al. EJNMMI Res. 2011 Aug 24;1(1):18. doi: 10.1186/2191-219X-1-18. EJNMMI Res. 2011. PMID: 22214432 Free PMC article.

6

Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.

Abbas N, Bruland ØS, Brevik EM, Dahle J. Abbas N, et al. Nucl Med Commun. 2012 Aug;33(8):838-47. doi: 10.1097/MNM.0b013e328354df7c. Nucl Med Commun. 2012. PMID: 22643311

7

Fractionated therapy of HER2-expressing breast and ovarian cancer xenografts in mice with targeted alpha emitting 227Th-DOTA-p-benzyl-trastuzumab.

Heyerdahl H, Abbas N, Brevik EM, Mollatt C, Dahle J. Heyerdahl H, et al. Among authors: abbas n. PLoS One. 2012;7(8):e42345. doi: 10.1371/journal.pone.0042345. Epub 2012 Aug 3. PLoS One. 2012. PMID: 22879947 Free PMC article.

8

Comparing high LET 227Th- and low LET 177Lu-trastuzumab in mice with HER-2 positive SKBR-3 xenografts.

Abbas N, Heyerdahl H, Bruland ØS, Brevik EM, Dahle J. Abbas N, et al. Curr Radiopharm. 2013 Jun 6;6(2):78-86. doi: 10.2174/18744710113069990017. Curr Radiopharm. 2013. PMID: 23551110

9

Personalized treatment with PARP inhibitors in advanced urothelial carcinoma: a case report and literature review.

Abbas N, Chehade L, Shamseddine A. Abbas N, et al. Ther Adv Med Oncol. 2024 Apr 16;16:17588359241245283. doi: 10.1177/17588359241245283. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38638285 Free PMC article.

10

Ethics guidelines for environmental epidemiologists: 2023 revision.

Etzel RA, Abbas NH, Anastario MP, Mustapha A, Osuolale O, Sarkar A, Soyiri IN, Whaibeh E, Soskolne CL. Etzel RA, et al. Among authors: abbas nh. Environ Epidemiol. 2024 Mar 12;8(2):e299. doi: 10.1097/EE9.0000000000000299. eCollection 2024 Apr. Environ Epidemiol. 2024. PMID: 38617426 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

537 results

Search Page